  Ephedrine section { margin-bottom: 20px; } table { border-collapse: collapse; } table, tr, th, td { border: 1px solid black; } th, td { padding: 0px 8px 0px 8px; text-align: left; vertical-align: top; } h3, p, ol.custom-counter, li { margin: 0px; padding: 0px; } .text-red { color: red; } .text-black { color: black; } ul.custom-dash { list-style: none; padding-left: 0; margin: 0; } ul.custom-dash > li { display: flex; align-items: flex-start; } ul.custom-dash > li::before { content: "–"; margin-right: 0.5em; flex-shrink: 0; line-height: 1; } ul.custom-dash > li > \*:not(::before) { flex: 1; } ul.custom-dash > li.no-dash::before { content: ""; width: 1em; margin-right: 0.5em; flex-shrink: 0; } /\* Change the ol style \*/ ol.custom-counter { list-style: none; padding-left: 0; counter-reset: custom calc(var(--start, 1) - 1); } ol.custom-counter li { counter-increment: custom; margin-bottom: 5px; } ol.custom-counter li::before { content: counter(custom) ") "; } /\* This is just for this file \*/ ul.custom-bullet-arrow { list-style: none; padding-left: 0; margin: 0; } ul.custom-bullet-arrow > li { display: flex; align-items: flex-start; } ul.custom-bullet-arrow > li::before { content: "↑"; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet-arrow > li.no-arrow::before { content: ""; width: 0.5em; margin-right: 0.5em; flex-shrink: 0; } ul.custom-bullet\_arrow ul { list-style-type: disc; padding-left: 1.5em; margin-top: 0.5em; } img.resized-200 { width: 200px; height: auto; } img.resized-400 { width: 400px; height: auto; } img.resized-600 { width: 600px; height: auto; } .mb-10px { margin-bottom: 10px; } .mb-20px { margin-bottom: 20px; } .mt-10px { margin-top: 10px; } .mt-20px { margin-top: 20px; } .reference-notes { font-size: 11px; } .text-indent-45px { text-indent: 45px; } .text-bold { font-weight: bold; } .text-italic { font-style: italic; } .text-center { text-align: center; }

### Ephedrine

Norepinephrine: NE

<table><tbody><tr><th style="width: 160px;">Class</th><td style="width: 450px;"><p>Alpha/Beta Adrenergic Agonist</p><p>A noncatecholamine sympathomimetic</p><p>An alkaloid, a class of naturally occurring chemical compounds found in plants of the <em>Ephedra</em> genus.</p></td></tr><tr><th>Quick notes</th><td><p>A stereoisomer of pseudoephedrine</p><p>Acts as both a direct and indirect sympathomimetic.</p><p>Less potent than epinephrine, but longer acting</p></td></tr><tr><th>Indications</th><td><p>Intraoperative hypotension with bradycardia or a low-normal HR.</p><p class="text-italic">Refer to the Phenylephrine note below this table.</p><p>Spinal or epidural-induced hypotension</p><p>To treat nasal congestion (pseudoephedrine)</p></td></tr><tr><th>Action</th><td><p><b>Directly</b> activates alpha-adrenergic and beta-adrenergic receptors.</p><p><b>Indirect effect:</b> Inhibits NE reuptake and increases the release of NE from vesicles in nerve cells.</p><p>This allows NE to remain in the synapse longer to bind to postsynaptic alpha and beta receptors.</p><p><b>Activates alpha-1-adrenergic receptors:</b> ↑ constriction of veins</p><p><b>Activates beta-1-adrenergic receptors:</b> ↑cardiac chronotropy and inotropy</p><p><b>Activates beta-2-adrenergic receptors:</b> ↑ bronchodilation</p></td></tr><tr><th>Coronary blood flow</th><td><p>It may ↑ coronary artery blood flow when treating hypotension during anesthesia due to it causing ↑CO and preload.</p><p>However, Ephedrine may also induce vasospasm and constriction of coronary arteries.</p></td></tr><tr><th>Onset</th><td><p>Rapid</p></td></tr><tr><th>Clinical Duration</th><td><p>15-30 minutes</p></td></tr><tr><th>Dosing IV</th><td><p>10 mg is the standard dose. 5-20 mg or 100-200 mcg/kg</p><p>Peds: 0.1-0.3 mg/kg (rarely used in peds)</p></td></tr><tr><th>IM or Sub Q uses</th><td><p>25 mg IM to the thigh post SAB with C-sections</p><p>25-50 mg added to local anesthesia for local infiltration prior to SAB</p></td></tr><tr><th>Absorption</th><td><p>Oral ephedrine attains peak plasma concentration at 1.8 hours and has a bioavailability of 88%.</p></td></tr><tr><th>Tachyphylaxis:</th><td><p>Yes, as early as the 2nd dose, less effective</p></td></tr><tr><th>Infusion dose</th><td><p>N/A</p></td></tr><tr><th>Diluent for infusion</th><td><p>Comes in a 50 mg/mL vial.</p><p>Dilute in a 5 or 10 mL syringe</p><p>add 1 mL vial to 4 mL NS or LR = 10 mg/mL</p><p>add 1 mL/vial to 9 mL to NS or LR = 5 mg/mL</p></td></tr><tr><th><p>Elimination</p><p>Half-life</p></th><td><p>6 hours</p><p>It varies significantly between the patient's urine pH.</p><p>It is eliminated more rapidly in acidic urine.</p></td></tr><tr><th>Metabolism</th><td><p>Most of the ephedrine is eliminated unchanged in the urine.</p><p>A small fraction is metabolized into NE via N-demethylation while the other portion undergoes oxidative deamination to form benzoic acid and other products.</p></td></tr><tr><th>Metabolites</th><td><p>NE</p></td></tr><tr><th>Route of elimination</th><td><p>The parent drug and its metabolites are primarily excreted through the urine.</p><p>60% of a dose is excreted unchanged in the urine.</p></td></tr><tr><th>Protein bounds</th><td><p>5-10 % bound to albumin</p><p>Total binding of around 20% is in the plasma</p></td></tr><tr><th>Pregnancy</th><td><p>Ephedrine crosses the placenta and can stimulate fetal beta-adrenergic receptors, increasing fetal heart rate and metabolic rate, which may lead to fetal acidosis.</p><p>It is still commonly used to treat or prevent maternal hypotension</p></td></tr><tr><th>Breast feed</th><td><p>It is excreted in breast milk and can cause side effects in the infant, such as irritability and sleep disturbances.</p></td></tr><tr><th>pH</th><td><p>4.5 and 6.5</p></td></tr><tr><th>Caution with:</th><td><p>Monoamine oxidase inhibitors (MAOIs)-may cause hypertensive crisis</p><p>Other sympathomimetic agents</p><p>Ergot alkaloids</p><p>Cardiac glycosides</p><p>Oxytocic drugs</p><p>Tricyclic antidepressants (TCAs)</p></td></tr><tr><th>Physical incompatibility</th><td><p>Solutions containing phenobarbitone sodium, pentobarbitone sodium, and hydrocortisone sodium succinate</p></td></tr><tr><th>Contraindications</th><td><p>Acute hypertension or tachycardia</p><p><b>Closed-angle glaucoma:</b> Ephedrine may worsen it</p><p><b>Pheochromocytoma:</b> It may cause severe hypertension.</p><p><b>Asymmetric septal hypertrophy (idiopathic hypertrophic subaortic stenosis):</b> Ephedrine can increase obstruction in this condition.</p><p><b>Tachyarrhythmias or ventricular fibrillation:</b> Ephedrine can exacerbate these cardiac issues.</p><p><b>Psychoneurosis:</b> This mental health condition is a contraindication for ephedrine use.</p></td></tr><tr><th>Vol of distribution</th><td><p>Oral ephedrine has a volume of distribution of 215.6 Liters. Ephedrine can cross the placental barrier</p></td></tr><tr><th><p>Antidote for toxicity -</p><p>PO use</p></th><td><p>For hypertension, 5 mg IV phentolamine mesylate or 100 mg orally.</p><p>Benzodiazepines may control convulsions.</p></td></tr><tr><th>Adverse reactions</th><td><p>Tachycardia</p><p>Hypertension</p><p>Myocardial Ischemia</p></td></tr><tr><th>Vol of distribution</th><td><p>Varies from 215.6 L or 3 L/kg</p></td></tr><tr><th>Storage</th><td><p>Room temperature</p></td></tr></tbody></table>

**Phenylephrine** is indicated for hypotension (with normal heart function) when the patient has a normal to ↑HR because it will also lower the heart rate due to reflex bradycardia.

**Ephedrine** increases the HR, and it is not the best option with an already elevated heart rate.

Effects of adrenergic agonists on organ systems

↑/↓: variable

| Drug | HR | MAP | CO | PVR | Bronchodilation | 
Renal

Blood Flow

 |
| --- | --- | --- | --- | --- | --- | --- |
| Ephedrine | ↑↑ | ↑↑ | ↑↑ | ↑ | ↑↑ | ↓↓ |
| Norepinephrine | ↓ | ↑↑↑ | ↑/↓ | ↑↑↑ | 0 | ↓↓↓ |
| Epinephrine | ↑↑ | ↑ | ↑↑ | ↑/↓ | ↑↑ | ↓↓ |
| Phenylephrine | ↓ | ↑↑↑ | ↓ | ↑↑↑ | 0 | ↓↓↓ |
| Dobutamine | ↑ | ↑ | ↑↑↑ | ↓ | 0 | ↑ |
| Dopamine | ↑/↑↑ | ↑ | ↑↑↑ | ↑ | 0 | ↑↑↑ |
| Isuprel | ↑↑↑ | ↓ | ↑↑↑ | ↓↓ | ↑↑↑ | ↑/↓ |
| Fenoldopam | ↑↑ | ↓↓↓ | ↑/↓ | ↓↓ | 0 | ↑↑↑ |

Morgan & Mikail’s Clinical Anesthesiology 7th Ed., 2022, p. 241 (↑/↓, variable)

Receptor selectivity

| Drug | A1 | A2 | B1 | B2 | DA1 | DA2 |
| --- | --- | --- | --- | --- | --- | --- |
| Ephedrine | +++ | ? | ++ | + | 0 | 0 |
| Norepinephrine | ++ | ++ | ++ | 0 | 0 | 0 |
| Epinephrine | ++ | ++ | +++ | ++ | 0 | 0 |
| Phenylephrine | +++ | + | 0 | 0 | 0 | 0 |
| Dobutamine | 0 | 0 | +++ | + | 0 | 0 |

Morgan & Mikail’s Clinical Anesthesiology 7th Ed., 2022, p. 240

**Alpha 1 (A1) receptors:** Vasoconstriction to both arteries and veins

**Alpha 2 (A2) receptors:** ↓ NE release and acetylcholine, result in ↓ pain, ↑ sedation

**Beta 1 (B1) receptors:** ↑HR, contractility, and CO

**Beta 2 (B2) receptors:** Bronchodilation

**Dopaminergic 1 (DA1) receptors:** ↑ Urine output

**Dopaminergic 2 (DA2) receptors:** Motivation and reward

Ephedrine

FDA Access Data (accessed 09/2025)

https://www.accessdata.fda.gov/drugsatfda\_docs/label/2022/213994s004lbl.pdf

Ephedrine

DrugBank (accessed 09/2025)

https://go.drugbank.com/drugs/DB01364

Morgan & Mikhail’s Clinical Anesthesiology 7th Ed., 2022

CH.14, Adrenergic Agonists & Antagonists, p.240-241

Stoelting's Pharmacology and Physiology in Anesthesia Practice 6th ed. 2022

CH. 17, Autonomic and Cardiovascular Pharmacology p. 303

Pamela Flood and James P. Rathmell

Ephedrine

National Library of Medicine

StatPearls (accessed 09/2025)

Alec K. Statler; Christopher V. Maani; Arpan Kohl

https://www.ncbi.nlm.nih.gov/books/NBK547661/

Effects of different doses of ephedrine spinal anesthesia on hemodynamics and adverse reactions in patients undergoing transurethral resection of the prostate

BMC Urology. 7/2025 (accessed 09/2025)

Shuyue Wang, Lei Yu, Jichen Fang & Yu Jiang

https://bmcurol.biomedcentral.com/artiShuyue

Alpha vs. Beta Adrenergic Receptors - Autonomic Nervous System - Physiology and Pharmacology

Medicosis Perfectionalis (accessed 09/2025)

https://www.youtube.com/watch?v=rM72LG5G7E4&t=146s

Dopamine receptors: from structure to function

American Physiological Society Journal 1998 Jan;78(1):189-225

C Missale 1, S R Nash, S W Robinson, M Jaber, M G Caron